<DOC>
	<DOCNO>NCT00480883</DOCNO>
	<brief_summary>Background : Cutaneous Leishmaniasis worldwide disease , endemic 88 country , show increase incidence last many decade . For last 60 year antimony compound consider treatment choice . Though use expensive , cumbersome , many adverse effect effective patient , search well alternative still go . Low dose antimony compound combination several agent show promise reduce adverse effect antimony compound without compromise efficacy . Allopurinol one agent though promising lack randomize , control trial prove efficacy . The main objective study evaluate low dose sodium stibogluconate combination allopurinol compare high dose sodium stibogluconate term efficacy adverse effect . Methods design : A multi-center randomized , control trial include 620 patient endemic area Leishmaniasis Pakistan undertaken ass research question . Parasitologically confirm cutaneous leishmaniasis include study . After evaluate inclusion/exclusion criterion patient randomize receive either meglumine antimoniate ( 20 mg/kg/day/intramuscular , till clinical resolution maximum 28 day ) combination meglumine antimoniate ( 10 mg/kg/day intramuscular ) allopurinol ( 20 mg/kg/day/oral ) till clinical resolution maximum 28 day . During treatment patient admit hospital monitor daily presence adverse effect . Follow period last six month patient visit research center assessment heal process monthly interval .</brief_summary>
	<brief_title>Treatment Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate Allopurinol</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Meglumine antimoniate</mesh_term>
	<criteria>Men woman 18 50 year old . Cutaneous ulcer , nodule , plaque , two week evolution require systemic therapy . Positive parasitological diagnosis cutaneous leishmaniasis . Patients voluntarily accept participate study sign inform consent . Disposition admit hospital , necessary , attend visit punctually ( initial , treatment follow ) . Acceptation use treatment cutaneous leishmaniasis study . Pregnant woman . Presence condition disease compromise patient immunologically ( i.e . diabetes , cancer , etc . ) , , , base judgment researcher , could alter course cutaneous leishmaniasis . Diffuse cutaneous leishmaniasis . Visceral leishmaniasis . Complete incomplete treatment antimony compound last three month . Patients history hepatic , renal , cardiovascular disease . Mentally neurologically disable patient consider fit approve participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>cutaneous leishmaniasis old world</keyword>
</DOC>